Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 10/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76896 | 0.91 | NPC1 (0.45) | KCNK3KCNK9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL76387 | 0.88 | KCNK3 (0.47) | KCNK3KCNK9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL77944 | 0.86 | RAB9A (0.45) | KCNK3KCNK9NPC1RAB9ATAS1R3 | |
| SCHEMBL10227845 | 0.86 | KCNK3 (0.54) | KCNK3KCNK9NPC1RAB9A | |
| SCHEMBL10227846 | 0.77 | ABCB1 (0.59) | KCNK3KCNK9NPC1RAB9A | |
| SCHEMBL10227844 | 0.75 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10718970 | 0.74 | ABCB1 (0.45) | KCNK3KCNK9HDAC8HDAC6NPC1 | |
| SCHEMBL5056927 | 0.74 | ABCB1 (0.42) | KCNK3KCNK9HDAC8HDAC6NPC1 | |
| SCHEMBL8772420 | 0.72 | ABCB1 (0.67) | — | |
| SCHEMBL25607328 | 0.70 | NPC1 (0.51) | NPC1RAB9ATAS1R3TAS1R1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |